These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18160519)

  • 1. Effects of Escherichia coli lipopolysaccharide on telithromycin pharmacokinetics in rats: inhibition of metabolism via CYP3A.
    Lee JH; Cho YK; Jung YS; Kim YC; Lee MG
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1046-51. PubMed ID: 18160519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time-dependent effects of Klebsiella pneumoniae endotoxin on the telithromycin pharmacokinetics in rats; restoration of the parameters in 96-hour KPLPS rats to the control levels.
    Lee JH; Cho YK; Jung YS; Kim YC; Lee MG
    Pulm Pharmacol Ther; 2008 Dec; 21(6):860-5. PubMed ID: 18976719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of E. Coli lipopolysaccharide on the pharmacokinetics of ipriflavone and its metabolites, M1 and M5, after intravenous and oral administration of ipriflavone to rats: decreased metabolism of ipriflavone due to decreased expression of hepatic CYP1A2 and 2C11.
    Chung HJ; Kang HE; Bae EJ; Lee I; Kim SG; Lee MG
    J Pharm Sci; 2008 Nov; 97(11):5024-36. PubMed ID: 18314883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Escherichia coli lipopolysaccharide on the metformin pharmacokinetics in rats.
    Cho YK; Choi YH; Kim SH; Lee MG
    Xenobiotica; 2009 Dec; 39(12):946-54. PubMed ID: 19925384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of acute renal failure on the pharmacokinetics of telithromycin in rats: negligible effects of increase in CYP3A1 on the metabolism of telithromycin.
    Lee JH; Lee MG
    Biopharm Drug Dispos; 2007 May; 28(4):157-66. PubMed ID: 17377958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of bacterial lipopolysaccharide on the pharmacokinetics of metformin in rats.
    Choi YH; Lee I; Lee MG
    Int J Pharm; 2007 Jun; 337(1-2):194-201. PubMed ID: 17275228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a newly developed ketolide antibiotic, telithromycin, on metabolism of theophylline and expression of cytochrome P450 in rats.
    Nosaka H; Nadai M; Kato M; Yasui K; Yoshizumi H; Miyoshi M; Zhao YL; Baba K; Takagi K; Hasegawa T
    Life Sci; 2006 May; 79(1):50-6. PubMed ID: 16423372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dependent pharmacokinetics of telithromycin after intravenous and oral administration to rats: contribution of intestinal first-pass effect to low bioavailability.
    Lee JH; Lee MG
    J Pharm Pharm Sci; 2007; 10(1):37-50. PubMed ID: 17498392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Faster clearance of omeprazole in rats with acute renal failure induced by uranyl nitrate: contribution of increased expression of hepatic cytochrome P450 (CYP) 3A1 and intestinal CYP1A and 3A subfamilies.
    Lee DY; Jung YS; Shin HS; Lee I; Kim YC; Lee MG
    J Pharm Pharmacol; 2008 Jul; 60(7):843-51. PubMed ID: 18549670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telithromycin pharmacokinetics in rat model of diabetes mellitus induced by alloxan or streptozotocin.
    Lee JH; Lee MG
    Pharm Res; 2008 Aug; 25(8):1915-24. PubMed ID: 18478316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic interaction between telithromycin and metformin in diabetes mellitus rats.
    Lee JH; Kang HE; Lee MG
    Xenobiotica; 2010 Mar; 40(3):217-24. PubMed ID: 20039777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of endotoxin derived from Escherichia coli lipopolysaccharide on the pharmacokinetics of drugs.
    Yang KH; Lee MG
    Arch Pharm Res; 2008 Sep; 31(9):1073-86. PubMed ID: 18806948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Faster clearance of omeprazole in mutant Nagase analbuminemic rats: possible roles of increased protein expression of hepatic CYP1A2 and lower plasma protein binding.
    Lee DY; Jung YS; Kim YC; Kim SY; Lee MG
    Biopharm Drug Dispos; 2009 Apr; 30(3):107-16. PubMed ID: 19288444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections.
    Ciervo CA; Shi J
    Curr Med Res Opin; 2005 Oct; 21(10):1641-50. PubMed ID: 16238904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo evaluation of the effect of puerarin on hepatic cytochrome p450-mediated drug metabolism.
    Kim SB; Yoon IS; Kim KS; Cho SJ; Kim YS; Cho HJ; Chung SJ; Chong S; Kim DD
    Planta Med; 2014 May; 80(7):561-7. PubMed ID: 24710899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial.
    Shi J; Montay G; Bhargava VO
    Clin Pharmacokinet; 2005; 44(9):915-34. PubMed ID: 16122280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats.
    Lai L; Hao H; Wang Q; Zheng C; Zhou F; Liu Y; Wang Y; Yu G; Kang A; Peng Y; Wang G; Chen X
    Drug Metab Dispos; 2009 Dec; 37(12):2399-407. PubMed ID: 19741040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic interaction between tamoxifen and ondansetron in rats: non-competitive (hepatic) and competitive (intestinal) inhibition of tamoxifen metabolism by ondansetron via CYP2D subfamily and 3A1/2.
    Yang SH; Suh JH; Lee MG
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):407-18. PubMed ID: 19504095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats.
    Choi YH; Suh JH; Lee JH; Cho IH; Lee MG
    J Pharm Pharmacol; 2010 Aug; 62(8):1084-8. PubMed ID: 20663044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor.
    Vieira ML; Zhao P; Berglund EG; Reynolds KS; Zhang L; Lesko LJ; Huang SM
    Clin Pharmacol Ther; 2012 Apr; 91(4):700-8. PubMed ID: 22398966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.